Advertisement
Advertisement
TOPIC
 / company

Eli Lilly

Eli Lilly
The latest news and top stories on Eli Lilly. An Indianapolis, Indiana-based entity in the pharmaceutical sector, Eli Lilly specialises in discovering, developing and manufacturing prescription drugs. It primarily serves healthcare providers and patients worldwide and is known for its pioneering work in insulin and the polio vaccine.
WuXi AppTec’s first quarter results marked the third consecutive quarter in which revenue remained above the 12 billion yuan mark. Photo: Shutterstock
China’s private sector

WuXi AppTec posts record first-quarter revenue on strong global demand

Earnings top estimates as multinational pharmaceutical firms ramp up investment and partnerships in China.

Science

China launches war on Alzheimer’s that may affect 10% of population by 2050

videocam
11
India

Opinion | Asia’s flood of cheap Ozempic generics opens gates to weight-loss abuse

videocam
Biomedicine: Companies

Global drug makers face pricing pressure as China targets affordable healthcare

As pharmaceutical firms navigate China’s aggressive pricing reforms, their profits could be squeezed further this year.

5
A pharmaceutical production line in Meishan, China. Photo: Costfoto/NurPhoto via Getty Images
India

Here comes the ‘Mounjaro bride’: Indian pre-wedding prep includes obesity drug

Many Indian marriages are arranged by families, often bringing expectations around physical appearance and financial status.

Banking & finance

Insilico Medicine signs AI drug development deal with Eli Lilly

Reaching development, regulatory and commercial milestones could see value of deal hit around US$2.75 billion.

Advertisement
Advertisement
Advertisement
Biomedicine: Companies

China biotech deals hit record as innovative drugs draw global interest

Deals reach US$60 billion in first quarter after analysts say Chinese biotech firms have shown substantial technological advancements.

The US$60 billion deal value represents a 73 per cent jump from the same period a year earlier. Photo: Shutterstock
China’s private sector

BASF launches biggest overseas project in China with green-powered mega-site

German chemical giant opens US$10 billion Zhanjiang complex, its largest overseas investment, as Beijing courts foreign capital.

China’s private sector

China’s obesity drug makers take on global giants as Novo Nordisk patent expires

Patent expiry of blockbuster drug opens door for Chinese drug makers to challenge multinationals in booming weight-loss market.

Made in China 2025

Global drug giants double down on China amid push for self-reliant supply chains

Multinationals are building self-reliant supply chains in China to insulate local markets from potential trade disruptions, say analysts.

AstraZeneca’s booth at the China International Supply Chain Expo in Beijing, July 17, 2025. Photo: EPA
China’s private sector

US reshoring drive casts shadow over China’s contract drug makers, analyst says

Strong order backlogs underpin earnings through 2027, but analysts warn longer-term demand is less certain as US firms reshore production.

Despite the headwinds, there is growing interest from multinational pharmaceutical companies in partnering with Chinese biotech firms. Photo: Getty Images
China’s private sector

Eli Lilly boosts China footprint with US$3 billion plan to expand supply chain

US firm is strengthening its China operations amid an intensifying expansion race with other pharmaceutical giants.

Crime in Hong Kong

Hong Kong woman, 30, arrested over illegal sale of slimming injection

Seized item was Mounjaro injection pen manufactured by US pharmaceutical company Eli Lilly, but labelled in Japanese.

Made in China 2025

China biotech outlicensing tops US$52 billion in first 2 months

The latest deals are Sino Biopharmaceutical’s partnership with France’s Sanofi and Antengene’s agreement with Belgium’s UCB.

The logo of Sino Biopharmaceutical is seen on a building in Beijing, April 22, 2021. Photo: VCG via Getty Images
Made in China 2025

Hong Kong-listed Chinese drug firms set to turn corner on rising sales, deals

Chinese pharmaceutical firms are poised for profit growth, driven by innovative drug sales and licensing deals, despite pricing pressures.

Pills are produced and packed at Modern Pharmaceutical’s factory. Photo: Shutterstock
China’s private sector

Wave of Chinese biotech deals builds with US$1.2 billion Harbour BioMed pact

Deal involving an antibody asset ‘goes beyond a traditional licensing transaction’, founder and CEO says.

Banking & finance

Mainland China’s investors pour into Hong Kong-listed drug stocks

An index tracking Stock Connect buying of 40 mainland drug firms gains 9 per cent in a week as China’s industry heft grows.

Advertisement
Advertisement
Advertisement
Biomedicine: Industry Trends

China could approve first AI-designed drug next year, Merck executive says

AI and genetics are creating a ‘seismic shift’ in the pharmaceutical business, experts on Asian Financial Forum panel say.

AI will allow drug makers to pick better molecules, make better medicines and improve molecule design, Amgen executive says. Photo: Shutterstock
Hong Kong healthcare and hospitals

Explainer | Worth the weight? What Hongkongers should know about slimming injections

Department of Health says prescription-only injections can only be sold in pharmacies under supervision of registered pharmacists.

Hong Kong healthcare and hospitals

Exclusive | No prescription, no problem: Hong Kong’s grey zone for weight-loss injections

Slimming injections cannot be sold or purchased in Hong Kong without doctor’s prescription, but some retailers are operating grey market.

Wellness

Weight rebound after stopping Ozempic, Wegovy? Not necessarily, new data says

New research suggests that many people who stop using GLP-1 drugs like Ozempic maintain their weight loss, countering previous studies.

New data suggests that many patients maintain weight loss after stopping GLP-1 drugs like Ozempic and Wegovy, which runs counter to previous findings cautioning that many patients will regain lost weight if treatment is interrupted. Photo: Shutterstock
Made in China 2025

Exclusive | China challenges US in AI drug race, but rivals still reliant on each other

While US biotech firms increase use of Chinese clinical data, Chinese firms need US counterparts for monetisation, investor and scientist says.

Leung Chuen-yan, partner for healthcare investment at Value Partners Group. Photo: Edmond So
Made in China 2025

Novartis, SciNeuro deal offers hope for 55 million suffering from Alzheimer’s

SciNeuro’s anti-amyloid programme is one of the firm’s key strategic research and development priorities to target the brain disease.

videocam
Made in China 2025

China’s weight-loss drug war: prices slashed up to 80% as obesity crisis worsens

Foreign, local firms fight for market share as number of overweight or obese adults could top 630 million by 2050, from 400 million in 2021.

Made in China 2025

Meow or never: China’s pudgy pets spark race for weight-loss drugs

Fosun and Huadong biotech labs eye feline obesity drugs as owners weigh cuteness against health risks.

The total pet population in China reached 430 million in 2024, with nearly one-third of urban cats classified as obese, according to the China Pet Industry Association. Photo: Shutterstock
IPO

China vital to Insilico’s plan to build biotech’s AI ‘Einstein’ for new drugs

US firm, backed by Fosun and Tencent, expands research base in China as it develops an AI-powered drug-discovery tool.

Insilico is training and testing an AI-powered drug-discovery tool to enable faster, cheaper and more successful drug discovery. Photo: Handout
IPO

Insilico Medicine leads 6 Hong Kong IPOs, capping banner fundraising year

Debutants raise total of US$899 million as exchange wraps up one of the most active months for IPOs since 2021.

India

As India’s US$70 million obesity drug market bulges, so does price war

Pharmaceutical giants like Lilly and Nordisk are battling for dominance in India’s weight-loss market with price cuts and early launches.

videocam
Advertisement
Advertisement
Advertisement
Help preserve 120 years of quality journalism.
SUPPORT NOW
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement